報價延遲最少15分鐘:2025/06/20 00:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.05 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.15/-0.74
|
|
企業價值
95.25M
|
| 資產負債 |
|
每股賬面淨值
4.71
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
25.98M
|
|
每股收益
0.47
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/20 00:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. |